Piperacillin plus tazobactam vs amikacin
It is very uncertain whether piperacillin plus tazobactam changes all‐cause mortality maximum compared with amikacin (very low certainty).
- RR 0.32 [0.01, 7.61]1 study · 59 participantsVery low
It is very uncertain whether piperacillin plus tazobactam changes all‐cause mortality maximum compared with amikacin (very low certainty).
It is very uncertain whether piperacillin plus tazobactam changes serious adverse events maximum compared with amikacin (very low certainty).
It is very uncertain whether ticarcillin plus clavulanic acid changes all‐cause mortality maximum compared with piperacillin plus gentamicin (very low certainty).
It is very uncertain whether ticarcillin plus clavulanic acid changes serious adverse events maximum compared with piperacillin plus gentamicin (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Dual probably leads to lower stroke compared with one antiplatelet agent (moderate certainty).
Dual showed no clear difference in vascular death compared with one antiplatelet agent (moderate certainty).
Dual showed no clear difference in myocardial infarction compared with one antiplatelet agent (high certainty).
Dual probably leads to lower stroke, myocardial infarction, or vascular death compared with one antiplatelet agent (moderate certainty).
Dual showed no clear difference in intracranial haemorrhage compared with one antiplatelet agent (low certainty).
Dual leads to higher extracranial haemorrhage compared with one antiplatelet agent (high certainty).
Dual leads to lower ischaemic stroke compared with one antiplatelet agent (high certainty).
Multiple probably leads to lower stroke compared with fewer antiplatelet agents (moderate certainty).
Multiple showed no clear difference in vascular death compared with fewer antiplatelet agents (moderate certainty).
Multiple showed no clear difference in myocardial infarction compared with fewer antiplatelet agents (high certainty).
Multiple probably leads to lower stroke, myocardial infarction, or vascular death compared with fewer antiplatelet agents (moderate certainty).
Multiple may leads to higher intracranial haemorrhage compared with fewer antiplatelet agents (low certainty).
Multiple leads to higher extracranial haemorrhage compared with fewer antiplatelet agents (high certainty).